Amoxicillin/clavulanate potassium
PreclinicalSmall molecule
Johnson & JohnsonAmoxicillin/clavulanate potassium is one of 27 small molecule programs targeting Appendicitis. It is currently in Preclinical.
2
Indications
10
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
37 competitors in Appendicitis
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Flagyl
DDePuy Orthopaedics
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Merrem
BB. Braun Medical Inc.
Approved
Monurol
MMeitheal
Approved
Betadine
BBecton, Dickinson and Company
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Urinary Tract Infection1 trial
Adolescent1 trial
Preoperative1 trial
Effect of Preoperative Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain
Completed·—·N/A·NCT03033147·72 enrolled
Pain1 trial
Effect of Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain
Unknown status·—·N/A·NCT03007342·78 enrolled
5 more indications
Intrabony Periodontal Defects1 trial
Bacterial Pneumonia1 trial
Complicated Intra-abdominal Infections1 trial
Sinusitis1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company